Dasatinib News and Research

RSS

Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.

New findings from a safety and feasibility clinical trial on removal of senescent cells

Mayo Clinic researchers, along with collaborators from Wake Forest School of Medicine and the The University of Texas Health Sciences Center at San Antonio, have published findings from a safety and feasibility clinical trial on the removal of senescent cells from a small group of patients with pulmonary fibrosis

7 Jan 2019

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

30 Aug 2018

New system for anti-cancer drug delivery offers hope to treat pediatric tumors

In most of the Western World, cancer is the primary cause of death in children over the age of one. Existing treatments for adult cancer patients are not particularly effective for children.

31 May 2018

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Revealing all the steps required to activate an enzyme called a protein kinase may identify new ways to target cancer, according to new University of Arizona-led research.

16 May 2018

Researchers test new cancer research model that may reduce cost and speed up studies

A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.

15 May 2018

Mayo Clinic study reveals link between senescent cells and bone loss in mice

Mayo Clinic researchers have reported a causal link between senescent cells - the cells associated with aging and age-related disease - and bone loss in mice.

21 Aug 2017

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukemia (CML) can safely increase treatment success and reduce negative side effects.

12 Jul 2017

Mayo Clinic researchers discover three new senolytic drugs

Mayo Clinic researchers have uncovered three new agents to add to the emerging repertoire of drugs that aim to delay the onset of aging by targeting senescent cells - cells that contribute to frailty and other age-related conditions.

9 Mar 2017

Mayo Clinic study finds link between biology of aging and idiopathic pulmonary fibrosis

A Mayo Clinic study has shown evidence linking the biology of aging with idiopathic pulmonary fibrosis, a disease that impairs lung function and causes shortness of breath, fatigue, declining quality of life, and, ultimately, death.

23 Feb 2017

Research findings point to inherited genetic basis of ALL risk in children

A late-breaking abstract being presented today during the 58th American Society of Hematology Annual Meeting and Exposition in San Diego identifies inherited genetic mutations in the gene IKZF1 that confer a higher likelihood of developing pediatric acute lymphocytic leukemia (ALL).

6 Dec 2016

Salvage alloSCT remains option for progressing CML patients

Research demonstrates the continuing role of allogeneic stem cell transplantation as a salvage option for patients with chronic myeloid leukaemia who progress to accelerated phase or blast crisis after tyrosine kinase inhibitor failure.

15 Jun 2016

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe.

15 Jun 2016

Long-term dasatinib findings support first-line use in CML

Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase-chronic myeloid leukaemia.

15 Jun 2016

Real-world CML management in line with ELN guidelines

The first-line treatment and monitoring of patients with chronic phase-chronic myeloid leukaemia is in accordance with the European LeukaemiaNet recommendations, finds a real-world clinical practice study.

18 May 2016

CML treatment-free remission criteria outlined

Treatment-free remission may be feasible in many patients with chronic myeloid leukaemia, say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase inhibitor therapy.

18 May 2016

BCR-ABL halving time indicates CML prognosis during front-line TKI

Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers.

21 Apr 2016

Vascular events in CML may not be linked to TKI therapy

The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest.

17 Mar 2016

Vascular Occlusion Risk Reviewed For CML New-Generation TKIs

A meta-analysis highlights the significantly increased risk of vascular occlusive events in patients with chronic myeloid leukaemia using some new-generation BCR-ABL tyrosine kinase inhibitors compared with use of imatinib.

17 Feb 2016

CNIO researchers reveal how combination of dasatinib and demcizumab reduces lung adenocarcinomas

Lung cancer is one of the most prevalent types of cancer, with more than 20,000 new cases diagnosed each year in Spain. Lung adenocarcinomas carrying oncogenic KRAS, the engine driving these tumours in 30% of cases, constitute the most aggressive sub-type because, unlike other types of lung cancer, there are no targeted therapies beyond the standard cisplatin-based treatment.

12 Feb 2016

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients.

22 Jan 2016

Dasatinib News and Research

New findings from a safety and feasibility clinical trial on removal of senescent cells

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

New system for anti-cancer drug delivery offers hope to treat pediatric tumors

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Researchers test new cancer research model that may reduce cost and speed up studies

Mayo Clinic study reveals link between senescent cells and bone loss in mice

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

Mayo Clinic researchers discover three new senolytic drugs

Mayo Clinic study finds link between biology of aging and idiopathic pulmonary fibrosis

Research findings point to inherited genetic basis of ALL risk in children

Salvage alloSCT remains option for progressing CML patients

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Long-term dasatinib findings support first-line use in CML

Real-world CML management in line with ELN guidelines

CML treatment-free remission criteria outlined

BCR-ABL halving time indicates CML prognosis during front-line TKI

Vascular events in CML may not be linked to TKI therapy

Vascular Occlusion Risk Reviewed For CML New-Generation TKIs

CNIO researchers reveal how combination of dasatinib and demcizumab reduces lung adenocarcinomas

Positive bosutinib response for elderly blast phase CML patient

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News